Skip to main content

Market Overview

Recap: Oxford Immunotec Global Q1 Earnings


Shares of Oxford Immunotec Global (NASDAQ:OXFD) remained unaffected at $11.76 after the company reported Q1 results.

Quarterly Results

Earnings per share were down 233.33% over the past year to ($0.20), which missed the estimate of ($0.15).

Revenue of $13,911,000 less by 5.94% from the same period last year, which beat the estimate of $13,450,000.


Earnings guidance hasn't been issued by the company for now.

Q2 revenue expected between $5,000,000 and $6,000,000.

How To Listen To The Conference Call

Date: May 05, 2020

Time: 10:01 PM ET

Webcast URL:

Price Action

52-week high: $17.77

52-week low: $8.37

Price action over last quarter: down 10.98%

Company Overview

Oxford Immunotec Global PLC is a diagnostic company. It is focused on developing and commercializing proprietary tests for the management of underserved immune regulated conditions. Its products include T-spot TB, T-spot-CMV, T-spot PRT,T-cell extend etc. The company's research and development activities focus on Chronic infections, Transplantation, Autoimmune and Inflammatory disease, Immune oncology.


Related Articles (OXFD)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at